» Articles » PMID: 35721114

A Novel Exosome-Relevant Molecular Classification Uncovers Distinct Immune Escape Mechanisms and Genomic Alterations in Gastric Cancer

Overview
Journal Front Pharmacol
Date 2022 Jun 20
PMID 35721114
Authors
Affiliations
Soon will be listed here.
Abstract

Gastric cancer (GC) is a highly heterogeneous malignant carcinoma. This study aimed to conduct an exosome-based classification for assisting personalized therapy for GC. Based on the expression profiling of prognostic exosome-related genes, GC patients in The Cancer Genome Atlas (TCGA) cohort were classified using the unsupervised consensus clustering approach, and the reproducibility of this classification was confirmed in the GSE84437 cohort. An exosome-based gene signature was developed Least Absolute Shrinkage and Selection Operator (LASSO) regression analysis. Immunological features, responses to immune checkpoint inhibitors, and genetic alterations were evaluated computational methods. Two exosome-relevant phenotypes (A and B) were clustered, and this classification was independent of immune subtypes and TCGA subtypes. Exosome-relevant phenotype B had a poorer prognosis and an inflamed tumor microenvironment (TME) relative to phenotype A. Patients with phenotype B presented higher responses to the anti-CTLA4 inhibitor. Moreover, phenotype B occurred at a higher frequency of genetic mutation than phenotype A. The exosome-based gene signature (GPX3, RGS2, MATN3, SLC7A2, and SNCG) could independently and accurately predict GC prognosis, which was linked to stromal activation and immunosuppression. Our findings offer a conceptual frame to further comprehend the roles of exosomes in immune escape mechanisms and genomic alterations of GC. More work is required to evaluate the reference value of exosome-relevant phenotypes for designing immunotherapeutic regimens.

Citing Articles

Exosome-related gene identification and diagnostic model construction in hepatic ischemia-reperfusion injury.

You Y, Chen S, Tang B, Xing X, Deng H, Wu Y Sci Rep. 2024; 14(1):22450.

PMID: 39341981 PMC: 11439056. DOI: 10.1038/s41598-024-73441-5.


Identification of an autophagy- and macropinocytosis-related prognostic signature for the prediction of prognosis and therapeutic response in gastric cancer.

Shi Y, Qiu A, Cui H, Lv H, Zhou L Genes Genomics. 2024; 46(10):1149-1164.

PMID: 39150612 DOI: 10.1007/s13258-024-01557-z.


Exosome-Mediated Communication in Thyroid Cancer: Implications for Prognosis and Therapeutic Targets.

Wang Y, Li Q, Yang X, Guo H, Ren T, Zhang T Biochem Genet. 2024; .

PMID: 38839646 DOI: 10.1007/s10528-024-10833-2.


Research advances in the molecular classification of gastric cancer.

Shi D, Yang Z, Cai Y, Li H, Lin L, Wu D Cell Oncol (Dordr). 2024; 47(5):1523-1536.

PMID: 38717722 PMC: 11466988. DOI: 10.1007/s13402-024-00951-9.


Characterization of the Prognosis and Tumor Microenvironment of Cellular Senescence-related Genes through scRNA-seq and Bulk RNA-seq Analysis in GC.

Guo G, Zhou Z, Chen S, Cheng J, Wang Y, Lan T Recent Pat Anticancer Drug Discov. 2023; 19(4):530-542.

PMID: 37807645 DOI: 10.2174/0115748928255417230924191157.


References
1.
Kong X, Fu M, Niu X, Jiang H . Comprehensive Analysis of the Expression, Relationship to Immune Infiltration and Prognosis of TIM-1 in Cancer. Front Oncol. 2020; 10:1086. PMC: 7498659. DOI: 10.3389/fonc.2020.01086. View

2.
Shitara K, Van Cutsem E, Bang Y, Fuchs C, Wyrwicz L, Lee K . Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6(10):1571-1580. PMC: 7489405. DOI: 10.1001/jamaoncol.2020.3370. View

3.
Lin H, Zhang L, Zhang C, Liu P . Exosomal MiR-500a-3p promotes cisplatin resistance and stemness via negatively regulating FBXW7 in gastric cancer. J Cell Mol Med. 2020; 24(16):8930-8941. PMC: 7417713. DOI: 10.1111/jcmm.15524. View

4.
Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X . Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018; 24(10):1550-1558. PMC: 6487502. DOI: 10.1038/s41591-018-0136-1. View

5.
Tang X, Guo T, Gao X, Wu X, Xing X, Ji J . Exosome-derived noncoding RNAs in gastric cancer: functions and clinical applications. Mol Cancer. 2021; 20(1):99. PMC: 8323226. DOI: 10.1186/s12943-021-01396-6. View